China Biotech Services Holdings
China Biotech Services Holdings Limited, commonly referred to as CBSH, is a prominent player in the biotechnology sector, headquartered in China (CN). Established in 2001, the company has made significant strides in providing comprehensive services across the biopharmaceutical and healthcare industries, focusing on drug development, clinical trials, and regulatory compliance. With a strong operational presence in major regions of China, CBSH offers a unique suite of services that includes laboratory testing, data management, and consulting. Their commitment to innovation and quality has positioned them as a trusted partner for pharmaceutical companies seeking to navigate the complexities of the biotech landscape. Notable achievements include successful collaborations with leading global firms, underscoring their market position as a key service provider in the rapidly evolving biotech industry.
DitchCarbon Score
How does China Biotech Services Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China Biotech Services Holdings's score of 28 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
China Biotech Services Holdings's reported carbon emissions
In 2022, China Biotech Services Holdings reported total carbon emissions of approximately 11,273,000 kg CO2e. This figure includes 2,200 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and about 11,237,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, Scope 3 emissions totalled approximately 33,700 kg CO2e, with significant contributions from business travel (15,600 kg CO2e), processing of sold products (6,500 kg CO2e), and waste generated in operations (11,600 kg CO2e). Comparatively, in 2021, the company reported total emissions of about 238,000 kg CO2e, with Scope 1 emissions at 38,000 kg CO2e and Scope 2 emissions at 159,000 kg CO2e. The Scope 3 emissions for that year were approximately 40,900 kg CO2e. This indicates a substantial increase in emissions from 2021 to 2022. Despite the increase in emissions, there are currently no publicly disclosed reduction targets or climate pledges from China Biotech Services Holdings. The absence of specific reduction initiatives or commitments suggests that the company may be in the early stages of developing a comprehensive climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 30,000 | 00,000 | 00,000 | 0,000 |
| Scope 2 | 467,000 | 000,000 | 000,000 | 00,000,000 |
| Scope 3 | 43,700 | 00,000 | 00,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
China Biotech Services Holdings is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
